Researchers at the Helmholtz-Zentrum Dresden-Rossendorf have developed a molecular marker to help doctors choose the right bladder cancer therapy. The radiotracer NECT-224 makes visible whether tumors carry a certain protein to which modern drugs can dock. In summer 2025, it was used successfully for the first time on a patient at Dresden University Hospital.
Good Newsletter von DieSachsen.de
Good Newsletter von DieSachsen.de
Articles are loaded
Your data is important to us and we would like to use cookies to further improve your incredible experience on DieSachsen.de.
